Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,320 JPY | +1.16% | +1.00% | -7.79% |
Apr. 30 | Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion | RE |
Apr. 29 | US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 8.35 and 10.1 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company has a low valuation given the cash flows generated by its activity.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.79% | 6.91B | B+ | ||
+20.68% | 43.27B | B- | ||
+25.28% | 22.92B | B+ | ||
+19.07% | 15.43B | - | ||
+13.24% | 12.95B | B+ | ||
+43.92% | 11.83B | B | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.13% | 5.55B | B+ | ||
+9.14% | 4.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4528 Stock
- Ratings Ono Pharmaceutical Co., Ltd.